Home - News - Details

US Research Oral Drug For Treatment Of New Crown Asks For More Than 5,000

US research oral drug for treatment of new crown asks for more than 5,000


The US pharmaceutical company Merck & Co. recently announced the results of its phase 3 clinical trial, which stated that its experimental oral drug "molnupiravir" used to treat new coronary pneumonia can reduce the hospitalization or death rate of severe high-risk patients by approximately 50%, but the drug has no effect on severely ill patients who have been admitted to the hospital.

Mild to moderate patients

Xu Shuchang, a government expert consultant and chair professor of the Department of Respiratory Medicine at CUHK, said yesterday that the newly developed oral COVID-19 drug treatment lasts for 5 days. It is believed to be suitable for patients with mild to moderate symptoms, and is mainly used for chronically ill patients or the elderly who are prone to complications. In order to reduce the chance of admission, he said that the cost of medicine is more expensive, about 700 US dollars per treatment course, which is equivalent to 5,450 yuan.

Xu said that studies have shown that if you start taking it within 5 days of onset, the effect will be better. The side effects of the new drug include nausea and diarrhea, but they are not common. The drug has been tried in areas where the Delta variant virus is endemic, which can also reduce the hospital admission rate. .

Xu also pointed out that in the third week of September, CUHK had completed the study on the third dose of the new crown vaccine. Among them, 40 people were vaccinated with the Kexing vaccine developed by the mainland, and 40 people were vaccinated with the vaccine developed by the mainland and Germany. For Bitex Vaccine, it is expected that in the third week of this month, there will be the results of the antibody level study in the first month of the third dose of vaccine, and the research team will continue to follow up.


Send Inquiry

You Might Also Like